News Focus
News Focus
icon url

steelyeye

06/24/20 7:49 PM

#305583 RE: Lemoncat #305563

Thanks for clarifying the confusion.

Your confusion was the intent of the question.




I suspect many sources of confusion will receive abundant clarity soon enough.

My cloudy crystal ball says news is coming sometime in the next three trading days, but I know nothing... just feel something.

Combining the previous safety across several hundred patients, previous antimicrobal and anti-inflammatory results, and these anti-viral in vitro results should make Brilacidin a very compelling avenue for the government to explore in the fight against COVID.

icon url

loanranger

06/24/20 11:50 PM

#305636 RE: Lemoncat #305563

"Your confusion was the intent of the question."
Bullshit. An ANSWER was the intent of the question and you and virtually everyone else have failed to provide a clear one.

"It was an outstanding result"
This was the result:
Brilacidin reduced the viral load in the samples 97 and 99% more than nothing at all did.

Here are the only two conclusions available for you to choose from:
Is my characterization of the results incorrect (and if so, how)?
OR
Do you really consider the reduction of the viral load in the B treated samples of 95 and 97% more than nothing at all to be an outstanding result?

How much of a reduction in the viral load would you expect nothing to cause?

This absurd conversation will stop when someone answers that very simple question. While it was not my intent, the question appears to have caused you some confusion or you would have answered it instead of taking a potshot at my intent in asking it.
Or would you care to suggest that the significance and real meaning of the phrase "reducing viral load by 95 percent and by 97 percent, compared to control", in the Company's words, doesn't really need to be understood?

Now we hear that "it does not follow that substance with marked viral load reduction vs. 'nothing' would lack potency" as if I had actually suggested that B lacked potency. I certainly didn't and I don't believe that anyone else did.

The intent of my questions from the first time they were asked has been to try to understand this headline well enough to assess whether it justified an immediate 88% increase in the closing share price followed by a 53% increase the next day:
"Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line"

To some, and it seems as if this applies to you, the share price increases themselves may have been enough and no further examination is required. That's up to you and I make no judgment about it. Please do me the same courtesy.